



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	360331	Kunzea Pain Relief Cream
ARTG entry for	Medicine Listed	
Sponsor	Australian Kunzea Pty Ltd	
Postal Address	209/87 Griffith Street, Coolangatta, QLD, 4225 Australia	
ARTG Start Date	8/04/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Preparations that contain, as their therapeutically active ingredient, Kunzea ambigua in topical products only, are subject to the following conditions: (i) Must include the label warning (EXTERN) - For external use only; and (ii) Must include the label warning (CHILD) - Keep out of reach of children (or words to that effect).

Products

1 . Kunzea Pain Relief Cream

Product Type	Single Medicine Product	Effective Date	8/04/2021
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Relieve feelings of general malaise/general debility
- Helps enhance/promote/increase vitality
- Maintain/support vitality
- Anti-inflammatory/relieve inflammation
- Analgesic/Anodyne/relieve pain
- Decrease/reduce/relieve mild rheumatic aches and pains
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Decrease/reduce/relieve mild joint pain/soreness
- Decrease/reduce/relieve symptoms of muscle injury/ailments
- Aid/assist/helps in the management of muscle sprain/strain
- Helps decrease/reduce/relieve symptoms of muscle sprain/strain
- Decrease/reduce/relieve muscle pain/ache/soreness
- Decrease/reduce/relieve mild nerve pain/neuralgia
- Decrease/reduce/relieve symptoms of mild sciatica
- Soothe skin
- Soothe/relieve skin inflammation
- Decrease/reduce/relieve skin irritation
- Decrease/reduce skin sensitivity
- Helps enhance/promote skin health
- Maintain/support skin health
- Maintain/support skin hydration

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Product presentation must only refer to mild nerve pain/neuralgia.

Product presentation must only refer to mild joint symptoms.

Product presentation must only refer to mild rheumatic aches/pains.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must only refer to mild sciatica.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Cream

Route of Administration Topical

Visual Identification

Active Ingredients

Kunzea ambigua leaf Oil essential	75 mg/g
Lavender Oil	5 mg/g
mixed (low-alpha type) tocopherols concentrate	10 mg/g
Rosmarinus officinalis leaf Extract liquid concentrate	5 mg/g
Equivalent: Rosmarinus officinalis (Dry)	35.5 mg/g

Other Ingredients (Excipients)

benzyl alcohol

cetostearyl alcohol

Coconut Oil

dehydroacetic acid

glycerol

glyceryl caprylate

Macadamia nut oil

medium chain triglycerides

potassium cetyl phosphate

purified water

sorbitan olivate

Soya Oil

Theobroma Oil

Vitellaria paradoxa

xanthan gum

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.